With one FDA approval in the bag, RNAi companies dare to dream

It took two decades and a few billion dollars to turn the discovery of RNA into an actual product. Now, two months after Alnylam Pharmaceuticals' pioneering FDA approval, scientists in the field say they're just getting started.

As STAT's Kate Sheridan reports, major drug makers have taken a renewed interest on the gene-silencing technologies, signing three big-money deals in the last month alone. And that has energized the handful of small companies that have toiled in RNAi for decades.

“You know that a field has matured when you stop talking about [technology] and you start talking about the drugs. We’re getting there,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. “I think we are just entering the golden age of RNAi.”

Read more.